Sp1291
ONE TREATMENT WITH TWO OPTIONS: ROUTE OF ADMINISTRATION FLEXIBILITY WITH ENTYVIO (VEDOLIZUMAB)
Date
May 19, 2024
Tracks
Related Products
SURVODUTIDE REDUCES LIVER FAT CONTENT, TRANSAMINASES, AND FIBROSIS MARKERS WITH GOOD SAFETY PROFILE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): AN INTERIM ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL
BACKGROUND: Survodutide is a novel glucagon receptor/glucagon-like peptide-1 receptor dual agonist under investigation for treatment in advanced liver disease associated with metabolic dysfunction-associated steatohepatitis (MASH), the most severe form of metabolic dysfunction-associated steatotic…
IBD Complications
This session will examine the outcomes of a spectrum of IBD related complications including colon cancer. It will also examine cost and efficient care delivery…
RNA SEQUENCING FROM BIOPSIES PERFORMED DURING FOOD ELIMINATION AND REINTRODUCTION IDENTIFIES SIGNATURES INVOLVED IN EARLY RECURRENCE OF EOE
RATIONALE: RNA sequencing studies have previously identified impaired barrier function and the subsequent proinflammatory response as critical to the pathogenies of EoE. However, the investigation into disease initiation is often limited by the inability to capture the disease early…
AGA Emerging Concepts in IBD: Fibrosis, Fistulas, Pouches and Frailty
Management of diseases of the ileo-anal pouch and perianal Crohn’s disease is challenging and involves multidisciplinary medical and surgical care. This session review the contemporary management of these complex clinical situations…